drugset / Trial / NCT01473108

Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862

NCT01473108

Phase 1 Completed 67 enrolled Bayer
RandomizedCrossoverSingle-blindOther

Summary

Pharmacodynamics, pharmacokinetics, safety, and tolerability will be investigated in this single dose study. In 5 treatment groups, different dosages of BAY94-8862 will be given in healthy male subjects.

Timeline

Start
2010-03-29
Primary completion
2010-11-30
Completion
2011-05-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Eplerenone Unknown 50 mg Oral
Subject Finerenone Small molecule 2.5 mg Oral
Subject Finerenone Small molecule 5 mg Oral
Subject Finerenone Small molecule 10 mg Oral
Subject Finerenone Small molecule 20 mg Oral

Indications

No indication recorded.